Drug interactions
Efgartigimod alfa + Nivolumab
Severity: Moderate
Efgartigimod alfa and Nivolumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
What this interaction means in plain words
Efgartigimod alfa and Nivolumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Efgartigimod alfa belongs to Miscellaneous; Nivolumab belongs to Oncology.
Why it happens
Efgartigimod blocks FcRn-mediated IgG recycling, which may accelerate catabolism of IgG-based nivolumab.
What to do
Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Consider timing nivolumab doses away from periods of maximal FcRn blockade only with specialist input.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Efgartigimod alfa and Nivolumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Nivolumab
- Nivolumab + Thalidomide Major
- Dexamethasone-tobramycin + Nivolumab Moderate
- Dexamethasone + Nivolumab Moderate
- Efgartigimod / hyaluronidase sc + Nivolumab Moderate
- Nivolumab + Ponesimod Moderate
- Nivolumab + Rozanolixizumab Moderate
Other interactions of Efgartigimod alfa
- Adalimumab + Efgartigimod alfa Moderate
- Ado-trastuzumab + Efgartigimod alfa Moderate
- Basiliximab + Efgartigimod alfa Moderate
- Bevacizumab + Efgartigimod alfa Moderate
- Brentuximab + Efgartigimod alfa Moderate
- Denosumab + Efgartigimod alfa Moderate
Frequently asked questions
Can I take Efgartigimod alfa with Nivolumab?
MediHelp rates the interaction as moderate. Efgartigimod alfa and Nivolumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
How serious is the interaction between Efgartigimod alfa and Nivolumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Consider timing nivolumab doses away from periods of maximal FcRn blockade only with specialist input.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
